公开(公告)号：US20230348421A1

公开(公告)日：2023-11-02

申请号：US18005952

申请日：2021-07-22

申请人： GENEORA PHARMA (SHIJIAZHUANG) CO., LTD.

发明人： Rui ZHANG ,  Liang YE ,  Mingxu MA ,  Wenyan WANG ,  Yusen DAI ,  Jingwei TIAN

IPC分类号： C07D401/12 ,  C07D409/12 ,  C07D401/06 ,  C07D405/14 ,  C07D405/12 ,  C07D211/58 ,  C07D487/08 ,  C07C275/26

CPC分类号： C07D401/12 ,  C07D409/12 ,  C07D401/06 ,  C07D405/14 ,  C07D405/12 ,  C07D211/58 ,  C07D487/08 ,  C07C275/26

摘要： The present invention relates to a novel compound as a 5-HT2A receptor inhibitor or inverse agonist, a preparation method therefor, and a pharmaceutical composition thereof. The present invention also relates to an application of the compound or the pharmaceutical composition in the preparation of a drug for treating 5-HT2A receptor-related diseases, the diseases comprising: non-motor symptoms caused by Parkinson's disease: delusion, illusion, depression, anxiety, cognitive disorder, and sleep disorder; dementia-related mental diseases; major depressive disorder; or negative symptoms of schizophrenia, etc.